Skip to main
MPLT

MPLT Stock Forecast & Price Target

MPLT Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 78%
Buy 22%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MapLight Therapeutics is displaying strong potential in the biopharmaceutical space with their innovative approach to targeting neural circuits for central nervous system disorders. With a proven track record through positive Phase 1 trials and a promising drug candidate with convenient dosing, the company's current value of $2.23B is expected to increase significantly upon successful results in ongoing trials for schizophrenia and Alzheimer's disease psychosis. Along with their other ongoing developments, MapLight Therapeutics has a positive financial outlook, but there is a potential for setbacks or slow market adoption.

Bears say

MapLight Therapeutics is a clinical-stage biopharmaceutical company that has strong financials and a promising lead candidate for central nervous system disorders. However, there is still a long road ahead as they are only in Phase 2 trials for their potential treatments. There is potential for market growth and achievement of exclusivity, but competition and potential side effects may hinder success.

MPLT has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 78% of analysts recommend a Strong Buy, 22% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MapLight Therapeutics Inc (MPLT) Forecast

Analysts have given MPLT a Strong Buy based on their latest research and market trends.

According to 9 analysts, MPLT has a Strong Buy consensus rating as of Jun 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MapLight Therapeutics Inc (MPLT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.